Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2014 | Research

PPM1D silencing by RNA interference inhibits the proliferation of lung cancer cells

Authors: Chen Zhang, Yuanzhuo Chen, Mingsong Wang, Xianzhen Chen, Yongxin Li, E Song, Xiaoqing Liu, Sekwon Kim, Hu Peng

Published in: World Journal of Surgical Oncology | Issue 1/2014

Abstract

Background

PPM1D (protein phosphatase, Mg²⁺/Mn²⁺ dependent, 1D) has been reported to be involved in multiple human tumors. This study was designed to investigate the functional role of PPM1D in lung cancer cells.

Methods

Expression levels of PPM1D were analyzed in A549 and H1299 cells by real-time PCR and Western blotting. Lentivirus-mediated short hairpin RNA (shRNA) was used to knock down PPM1D expression in both cell lines. The effects of PPM1D on lung cancer cell growth were investigated by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), colony formation and flow cytometry assays.

Results

Knockdown of PPM1D in lung cancer cells resulted in decreased cell proliferation and impaired colony formation ability. Moreover, flow cytometry analysis showed that knockdown of PPM1D arrested cell cycle at the G₀/G₁ phase. Furthermore, PPM1D silencing downregulated the expression of cyclin B1 in H1299 cells. Therefore, it is reasonable to speculate that the mechanisms by which PPM1D knockdown alleviates cell growth may be partly via the induction of cell cycle arrest due to the suppression of cyclin B1.

Conclusions

These results suggest that PPM1D silencing by RNA interference (RNAi) may be a potential therapeutic approach for the treatment of lung cancer.

Available only for authorised users

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127: 2893-2917. 10.1002/ijc.25516.CrossRefPubMed

Pirozynski M: 100 years of lung cancer. Respir Med. 2006, 100: 2073-2084. 10.1016/j.rmed.2006.09.002.CrossRefPubMed

Schwartz AG, Prysak GM, Bock CH, Cote ML: The molecular epidemiology of lung cancer. Carcinogenesis. 2006, 28: 507-518. 10.1093/carcin/bgl253.CrossRefPubMed

Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62: 10-29. 10.3322/caac.20138.CrossRefPubMed

Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007, 18: 317-323.CrossRefPubMed

Liu X, Sempere LF, Guo Y, Korc M, Kauppinen S, Freemantle SJ, Dmitrovsky E: Involvement of microRNAs in lung cancer biology and therapy. Transl Res. 2011, 157: 200-208. 10.1016/j.trsl.2011.01.001.PubMedCentralCrossRefPubMed

Chen L, Liang Z, Tian Q, Li C, Ma X, Zhang Y, Yang Z, Wang P, Li Y: Overexpression of LCMR1 is significantly associated with clinical stage in human NSCLC. J Exp Clin Cancer Res. 2011, 30: 18-10.1186/1756-9966-30-18.PubMedCentralCrossRefPubMed

Skrzypski M, Dziadziuszko R, Jassem J: MicroRNA in lung cancer diagnostics and treatment. Mutat Res. 2011, 717: 25-31. 10.1016/j.mrfmmm.2011.04.002.CrossRefPubMed

Stein EV, Price DK, Figg WD: shRNA technology, investigating Ras-dependent cancer. Cancer Biol Ther. 2009, 8: 1798-1799. 10.4161/cbt.8.19.9681.CrossRefPubMed

10.

Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M, Donehower LA: The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev. 2008, 27: 123-135. 10.1007/s10555-008-9127-x.PubMedCentralCrossRefPubMed

11.

Nannenga B, Lu X, Dumble M, Maanen MV, Nguyen TA, Sutton R, Kumar TR, Donehower LA: Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice. Mol Carcinog. 2006, 45: 594-604. 10.1002/mc.20195.CrossRefPubMed

12.

Lu X, Nannenga B, Donehower LA: PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev. 2005, 19: 1162-1174. 10.1101/gad.1291305.PubMedCentralCrossRefPubMed

13.

Shreeram S, Demidov ON, Hee WK, Yamaguchi H, Onishi N, Kek C, Timofeev ON, Dudgeon C, Fornace AJ, Anderson CW, Minami Y, Appella E, Bulavin DV: Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell. 2006, 23: 757-764. 10.1016/j.molcel.2006.07.010.CrossRefPubMed

14.

Fujimoto H, Onishi N, Kato N, Takekawa M, Xu XZ, Kosugi A, Kondo T, Imamura M, Oishi I, Yoda A, Minami Y: Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase. Cell Death Differ. 2006, 13: 1170-1180. 10.1038/sj.cdd.4401801.CrossRefPubMed

15.

Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto T, Inazawa J: PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res. 2003, 63: 1876-1883.PubMed

16.

Loukopoulos P, Shibata T, Katoh H, Kokubu A, Sakamoto M, Yamazaki K, Kosuge T, Kanai Y, Hosoda F, Imoto I, Ohki M, Inazawa J, Hirohashi S: Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci. 2007, 98: 392-400. 10.1111/j.1349-7006.2007.00395.x.CrossRefPubMed

17.

Castellino RC, De Bortoli M, Lu X, Moon SH, Nguyen TA, Shepard MA, Rao PH, Donehower LA, Kim JY: Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol. 2008, 86: 245-256. 10.1007/s11060-007-9470-8.PubMedCentralCrossRefPubMed

18.

Lambros MB, Natrajan R, Geyer FC, Lopez-Garcia MA, Dedes KJ, Savage K, Lacroix-Triki M, Jones RL, Lord CJ, Linardopoulos S, Ashworth A, Reis-Filho JS: PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. Mod Pathol. 2010, 23: 1334-1345. 10.1038/modpathol.2010.121.CrossRefPubMed

19.

Parssinen J, Alarmo EL, Khan S, Karhu R, Vihinen M, Kallioniemi A: Identification of differentially expressed genes after PPM1D silencing in breast cancer. Cancer Lett. 2008, 259: 61-70. 10.1016/j.canlet.2007.09.019.CrossRefPubMed

20.

Tan DSP, Lambros MBK, Rayter S, Natrajan R, Vetcheva R, Gao Q, Marchio C, Geyer FC, Savage K, Parry S, Fenwick K, Tambler N, Mackay A, Dexterm T, Jameson C, McCluggage WG, Williams A, Graham A, Faratian D, El-Bahrawy M, Paige AJ, Gabra H, Gore ME, Zvelebil M, Lord CJ, Kaye SB, Ashworth A, ReispFilho JS: PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res. 2009, 15: 2269-2280. 10.1158/1078-0432.CCR-08-2403.CrossRefPubMed

21.

Li GB, Zhang XL, Yuan L, Jiao QQ, Liu DJ, Liu J: Protein phosphatase magnesium-dependent 1δ (PPM1D) mRNA expression is a prognosis marker for hepatocellular carcinoma. PLoS One. 2013, 8: e60775-10.1371/journal.pone.0060775.PubMedCentralCrossRefPubMed

22.

Ma PC: Personalized targeted therapy in advanced non-small cell lung cancer. Cleve Clin J Med. 2012, 79 (Electronic Suppl 1): eS56-eS60.PubMed

23.

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M, West Japan Oncology Group: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010, 11: 121-128. 10.1016/S1470-2045(09)70364-X.CrossRefPubMed

24.

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011, 29: 2866-2874. 10.1200/JCO.2010.33.4235.CrossRefPubMed

25.

Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE, Vande Woude GF, O’Connor PM, Appella E: Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci U S A. 1997, 94: 6048-6053. 10.1073/pnas.94.12.6048.PubMedCentralCrossRefPubMed

26.

Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, Kallioniemi A, Fornace AJ, Appella E: Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet. 2002, 31: 210-215. 10.1038/ng894.CrossRefPubMed

27.

Koom WS, Park SY, Kim W, Kim M, Kim JS, Kim H, Choi IK, Yun CO, Seong J: Combination of radiotherapy and adenovirus-mediated p53 gene therapy for MDM2-overexpressing hepatocellular carcinoma. J Radiat Res. 2012, 53: 202-210. 10.1269/jrr.11110.CrossRefPubMed

28.

Bulavin DV, Phillips C, Nannenga B, Timofeev O, Donehower LA, Anderson CW, Appella E, Fornace AJ: Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet. 2004, 36: 343-350. 10.1038/ng1317.CrossRefPubMed

29.

Ruark E, Snape K, Humburg P, Loveday C, Bajrami I, Brough R, Rodrigues DN, Renwick A, Seal S, Ramsay E, Duarte Sdel V, Rivas MA, Warren-Perry M, Zachariou A, Campion-Flora A, Hanks S, Murray A, Ansari Pour N, Douglas J, Gregory L, Rimmer A, Walker NM, Yang TP, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C: Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature. 2013, 493: 406-410.PubMedCentralCrossRefPubMed

30.

Wang P, Rao J, Yang H, Zhao H, Yang L: PPM1D silencing by lentiviral-mediated RNA interference inhibits proliferation and invasion of human glioma cells. J Huazhong Univ Sci Technolog Med Sci. 2011, 31: 94-99. 10.1007/s11596-011-0157-1.CrossRefPubMed

31.

Satoh N, Maniwa Y, Bermudez VP, Nishimura K, Nishio W, Yoshimura M, Okita Y, Ohbayashi C, Hurwitz J, Hayashi Y: Oncogenic phosphatase Wip1 is a novel prognostic marker for lung adenocarcinoma patient survival. Cancer Sci. 2011, 102: 1101-1106. 10.1111/j.1349-7006.2011.01898.x.CrossRefPubMed

Title: PPM1D silencing by RNA interference inhibits the proliferation of lung cancer cells
Authors: Chen Zhang
Yuanzhuo Chen
Mingsong Wang
Xianzhen Chen
Yongxin Li
E Song
Xiaoqing Liu
Sekwon Kim
Hu Peng
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/1477-7819-12-258

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

PPM1D silencing by RNA interference inhibits the proliferation of lung cancer cells

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Expression of fibroblast specific protein-1 in pleural tuberculosis and its clinical biological significance

Adenoma of the nipple projecting out of the nipple: curative resection without excision of the nipple

Rare solitary neoplasm of the costa in an adult: a case report

Comparison of laparoscopic peritoneal vaginoplasty and sigmoid colon vaginoplasty performed during radical surgery for primary vaginal carcinoma

Is laparoscopic colorectal cancer surgery associated with an increased risk in obese patients? A retrospective study from China

Follow-up study of unilateral renal function after nephrectomy assessed by glomerular filtration rate per functional renal volume